Synapse - law for life sciences - September 2018

This month on Synapse

Biosimilars – an overview of the route to market in the US and Europe

Taylor Wessing and Willkie Farr & Gallagher present the first of three webinars covering various aspects of market access for biosimilars. In this webinar they cover the basics of the regulatory system in the US and Europe; the history of approvals and launches in the US and Europe; and an overview of the "patent dance" under the BPCIA and contrast to the position in Europe.

Topical issues

New government code of conduct for data-driven technologies in the health and care

Nick Harrison explains what is in the Department of Health and Social Care (DHSC) has published in its initial Code of Conduct for the use of data-driven technology in the health and care sectors.

Brexit and the life sciences sector: the UK Government’s offer to the EU

In the first of three articles about the possible outcomes of Brexit and what they mean for the life sciences sector, in particular the authorisation of medicines and medical devices, Tim Worden and Paul England examine the Government's 'Chequers' offer to the UK on a future relationship.

Brexit and the life sciences sector: what is the relevance of the transition (implementation) period

In the second of three articles about the possible outcomes of Brexit and what they mean for the life sciences sector, in particular the authorisation of medicines and medical devices, Paul England examines the relevance of the transition (implementation) period.

Brexit and the life sciences sector: guidelines for 'no deal'

In the final article about the possible outcomes of Brexit and what they mean for the life sciences sector, in particular the authorisation of medicines and medical devices, Matthew Royle and Paul England address the guidelines issued by the UK Government and EU Commission in the event of a ‘no deal’ Brexit.